Navigation Links
GEN Reports on Novel Hit-to-Lead Drug Discovery Strategies
Date:7/8/2008

NEW ROCHELLE, N.Y., July 8 /PRNewswire/ -- Biotech and pharmaceutical firms are developing a host of new technologies designed to streamline the complicated drug discovery process, reports Genetic Engineering and Biotechnology News (GEN). Most successful approaches rely on a combination of high-throughput screening methods, miniaturization techniques, and advanced data-analysis tools, according to an article in the July issue (http://www.genengnews.com/articles/chitem.aspx?aid=2527) of GEN.

"The key goal for companies trying to develop new drugs is to find the best series of compounds that will optimize their chances of turning promising hits into even more promising leads," notes John Sterling, Editor in Chief of GEN.

Merck, for example, tries to make certain that its scientists work on physiologically relevant targets and assays during early-stage drug discovery research. For target identification the company uses RNAi technology in human cell lines. Multiparametric assays then generate biological activity profiles that can often provide valuable insight into complex disease models.

Pharmacopeia's screening platform is based on its ECLiPS(R) (encoded combinatorial libraries on polymeric support) technology. Three steps are involved in the firm's screening process. A primary high-throughput approach screens eluate from multiple beads. A follow-up protocol screens single bead eluates from those sublibraries, which demonstrate activity in the assay. Finally, company scientists submit beads for a decoding process, which is how they identify the structure of compounds in the active wells in step two.

Also discussed in the GEN article is drug discovery activities taking place at GlaxoSmithKline, Fujifilm, Archemix, and the Southern Research Institute.

For a copy of the July issue of GEN, please call (914) 740-2122, or email: ebicovny@liebertpub.com

Genetic Engineering and Biotechnology News (http://www.genengnews.com), which is published 21 times a year by Mary Ann Liebert, Inc., is the most widely read biotechnology news magazine worldwide. It includes articles on Drug Discovery, Bioprocessing, OMICS, Biobusiness, and Clinical Research and Diagnostics.

Contact: John Sterling, Editor in Chief, Genetic Engineering & Biotechnology News

Ph: (914) 740-2196, jsterling@genengnews.com


'/>"/>
SOURCE Genetic Engineering and Biotechnology News
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Galaxy Nutritional Foods Reports FY2008 Results
2. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
3. Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter
4. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
5. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
6. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
7. Cord Blood America Reports CorCell, Its Major Acquisition in 2006, Turns Profitable
8. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
9. Rosetta Genomics Reports First Quarter 2008 Financial Results
10. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
11. Advance Nanotech Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita ... miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject of ... now. , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
Breaking Biology Technology:
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
Breaking Biology News(10 mins):